#USA #New York #Rosen Law Firm #REGENXBIO #RGNX

A Call to Action for REGENXBIO Investors

In a critical development for investors of REGENXBIO, Inc. (NASDAQ: RGNX), the Rosen Law Firm, renowned for its advocacy of investor rights, has issued an important reminder. Stockholders who acquired shares during the period from February 9, 2022, to January 27, 2026, have an opportunity to participate in a securities fraud class action lawsuit that addresses significant allegations against the company.

Why This Matters

The lawsuit against REGENXBIO centers around its plans related to the treatment candidate, RGX-111, aimed at combating severe Mucopolysaccharidosis Type I (also known as Hurler syndrome). Allegations suggest that the company misled investors by providing overly optimistic assertions regarding the success of RGX-111's clinical trials based on selective data. Investors were reportedly provided with positive information while crucial adverse data was allegedly concealed, which misrepresented the true efficacy and safety of the treatment.

As the legal proceedings move forward, the Rosen Law Firm emphasizes the importance of acting swiftly. A key deadline is approaching—April 14, 2026—by which potential lead plaintiffs must file their motions to serve as representatives in this class action.

What Should Investors Do?

Investors who qualify can potentially receive compensation without incurring upfront fees, thanks to a contingency fee arrangement. If you're affected and considering joining the class, it's crucial to act promptly. You can fill out the form provided by the Rosen Law Firm or reach out directly to Phillip Kim, Esq., for guidance via phone or email.

This legal action is an important step for investors seeking accountability and recovery of losses suffered due to alleged misrepresentations by REGENXBIO. Whether participating in the lawsuit or simply monitoring its progress, investors are encouraged to remain informed.

About Rosen Law Firm

The Rosen Law Firm stands out in a highly competitive field with its proven track record in securities class actions and shareholder derivative cases. Notably, the firm achieved one of the largest-ever settlements against a Chinese company and was recognized as a leader in the field for the number of securities class action settlements reached annually. With extensive experience and resources, the firm has secured substantial recoveries for investors, marking it as a preferred counsel option for anyone looking to navigate these complex legal landscapes.

Key Takeaways for Interested Investors

• - Join the Class Action: If you purchased REGENXBIO shares during the stated period, consider joining the lawsuit by following the Rosen Law Firm’s protocol.
• - Understand Your Rights: As an investor, you have the right to select your counsel and remain informed about legal proceedings that impact your investments.
• - Stay Updated: The situation can evolve rapidly, so staying connected with resources, such as the Rosen Law Firm's updates on social media and their official channels, can ensure you are not left in the dark.

Conclusion

The upcoming deadline marks a crucial point for REGENXBIO investors. By taking action now, potential plaintiffs can advocate not just for their financial interests but also enhance accountability within business practices. Whether through legal representation or by watching the proceedings unfold, participating in this class action might provide a pathway to recovery for those affected.

Be sure to follow the Rosen Law Firm on platforms like LinkedIn and Twitter for continuous updates about the case and other related legal insights.